ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
ATB Therapeutics has raised $57.2M in total funding. The most recent round was Series A. The last funding was announced in November 2024.
ATB Therapeutics's investors include EQT Life Sciences, MRL Ventures Fund, V-Bio Ventures, SFPIM, WE International.
ATB Therapeutics is headquartered in Aye, Belgium.
ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
ATB Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ATB Therapeutics — Funding & Investors." VCBacked, November 18, 2024, https://www.vcbacked.co/company/atb-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). ATB Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/atb-therapeutics
{{cite web |title=ATB Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/atb-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated